Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ThreeWire: Marketing Meets Patient Recruiting for Device Trials

This article was originally published in Start Up

Executive Summary

Regulatory requirements for devices are becoming more demanding, making clinical trials more complex and costly. ThreeWire's marketing-based approach looks to speed patient recruitment, a benefit for start-ups since, in clinical studies, time is definitely money.

You may also be interested in...



CVRx: Can Devices Succeed Where Drugs Fail for High Blood Pressure?

With hypertension reaching pandemic proportions, more and more people are not successfully treated with the drugs that, until now, have been the only therapy. CVRx is the first to develop a device to provide patients with another option.

Northstar's Buzz

The hottest clinical space in medical devices may very well be stroke and the hottest technology area could be neurostimulation. Northstar combines both opportunities with an innovative system that addresses a largely un-addressed market--chronic stroke--by stimulating the cortex of the brain. And as promising as this therapy is, it may only be the tip of the iceberg for Northstar

Financing Strategies for an Overheated Device Market

At In3 West, a medical device conference held in Las Vegas recently, Windhover Information convened a panel of venture investors to ask them what's in store for device companies seeking investments in the near future, and to address one nagging question: whether or not the heady funding levels of 2007 are sustainable, or even desirable. Certainly exits have become more challenging; consolidation has removed certain would-be acquirers and the IPO market has become more demanding; no company will get out there without at least $30 to $40 million in revenues, several on the panel felt. Others were feeling the pressure of having to carry portfolio companies for even longer periods of time; more complex technologies, lag times at the FDA, and the need to get companies not only to the commercial stage but to a revenue ramp were pushing up the number of years to an exit and total investment dollars. Many were optimistic that early stage deals, exits by acquisition and other unusual phenomena would continue to happen; but selectivity was the theme of the day.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM016193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel